Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 4, 1999

View Archived Issues

BMS discusses next-to-launch products at investor conference

IDEA obtains promising results in pilot study of transdermal insulin

Human Genome Sciences updates R&D progress

Millennium identifies key mediator of allergic immune response

Results from lead-in phase of Xcytrin trial support continued patient enrollment

Ribavirin derivative exerts potent synergistic antiviral activity

Zeffix approved in Taiwan for chronic HBV infection

Vertex commences pilot phase II study of VX-745 for rheumatoid arthritis

Tegaserod is highly effective and well tolerated in large North American study

ImClone receives payment from AHP for gonorrhea vaccine milestone

Axonyx cleared to initiate phase I clinical trials of phenserine

Merck KGaA branches out into women's healthcare with announced acquisition

Structurally modified bisphosphonate with improved activity and oral bioavailability: ISA-13-1

Pfizer downplays media hype about Viagra for women

Pliva patents novel antibiotics from the macrolide class

Agents for urinary incontinence, pollakiuria in early development at Fujisawa

Cytokine-inhibitory pyrazoles from Abbott: preparation, activity and use

Merck's new antidiabetic agents modulate insulin receptor tyrosine kinase activity

Novel antidepressants with combined 5-HT1A autoreceptor/5-HT transporter activity

Warner-Lambert-AHP merger will create world's largest pharmaceutical company

CMV retinitis in AIDS patients: HAART alone is effective

Lilly discloses methods of inhibiting multidrug resistance

Combinations of ERL-080A, RAD and/or ciclosporin prolong heart xenograft survival

Brequinar + ciclosporin for islet xenograft rejection: results using a pig-to-rat model

Beneficial effects reported for FR-167653 in rat model of myocarditis

FDA approves once-daily dosing for Videx tablets

Bradykinin B2 antagonist active in a guinea pig model of allergic bronchitis

In vivo bronchodilating, antiallergic effects documented for S-1319

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...